The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

The drug, Alyftrek, works by regulating the flow of water and salt in and out of organs in CF patients, improving their overall function. It helps fix a faulty protein (CFTR) in their cells ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

The National Institute for Health and Care Excellence (Nice) is assessing the clinical and cost effectiveness of Alyftrek – a new once-a-day pill to treat the condition. The drug, also known as ...